LOGIN  |  REGISTER
Recursion

Latest Leadership Change News

Modivcare Announces Changes to Board of Directors

April 25
Last Trade: 1.47 -0.07 -4.55

Seasoned Executive Daniel Silvers Brings Decades of Experience in Corporate Finance, Capital Allocation and Public Company Governance DENVER / Apr 25, 2025 / Business Wire / Modivcare Inc. (“Modivcare” or the “Company”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Daniel Silvers has been...Read more


West Pharmaceutical Announces Leadership Changes

April 24
Last Trade: 214.55 3.96 1.88

Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning...Read more


Encompass Health announces promotion of Patrick Tuer to newly established COO position

April 24
Last Trade: 113.37 11.96 11.79

BIRMINGHAM, Ala., April 24, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced the promotion of Patrick Tuer from group president to the newly established position of chief operating officer (COO), effective immediately. As COO, Tuer will oversee hospital operations across the organization and will continue reporting to Mark Tarr, president and chief executive officer (CEO) of Encompass Health. "Pat brings...Read more


Integer Announces CEO Succession Plan

April 24
Last Trade: 123.41 1.95 1.61

Joseph Dziedzic to retire as President and CEO Payman Khales appointed President and CEO effective October 24, 2025  PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors,...Read more


Brookdale Senior Living Appoints Joshua Hausman to Board of Directors

April 24
Last Trade: 6.30 0.06 0.96

Brings Significant Healthcare and Private Capital Investing Expertise, including in Facilities-Based and Senior Care Services Companies Company's Average Director Tenure to be Less Than Four Years after Annual Meeting NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today announced that its Board of Directors (the "Board") has appointed Joshua Hausman,...Read more


STAAR Surgical Announces Changes to Board of Directors

April 24
Last Trade: 18.03 0.15 0.84

LAKE FOREST, Calif. / Apr 24, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company’s Board from 2014-2022, as a director, effective April 24, 2025. The Company also...Read more


Helix BioPharma Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers

April 24
Last Trade: 0.78 0.00 0.00

Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer (“COO”) and Jessica Kourniaktis, DPhil, as Director of Communications of the Company. Ms. Kandziora is...Read more


Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

April 23
Last Trade: 9.38 -0.07 -0.74

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor...Read more


HEALWELL AI Unveils Strategic Changes to Executive Leadership Team to Drive the Next Phase of Integration, Growth and Shareholder Value Creation

April 23
Last Trade: 1.46 -0.01 -0.68

Toronto, Ontario--(Newsfile Corp. - April 23, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, today announces a number of key executive appointments to the Company's senior leadership team to reflect HEALWELL's focus on building a high-impact leadership team to guide the Company as it shifts to its next phase of growth, scaling...Read more


Microbot Medical Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

April 23
Last Trade: 2.60 0.17 7.00

The addition of a seasoned VP of Marketing compliments the recent hiring of the Company’s VP of Sales to establish its commercialization readiness infrastructure Positive data from the recently published pivotal study raises confidence that LIBERTY® will be well received in the market HINGHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic...Read more


Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

April 23
Last Trade: 0.48 -0.01 -2.88

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa...Read more


Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

April 23
Last Trade: 0.79 -0.05 -6.49

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company’s Board of Directors where he will serve as chair of the Audit Committee and on the Compensation...Read more


Clover Health Announces Changes to Board of Directors

April 22
Last Trade: 3.43 -0.04 -1.15

WILMINGTON, Del., April 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that after four years of distinguished service, Lee A. Shapiro, a member of Clover Health’s Board of Directors, has notified the Company of his intention not to stand for reelection to the Board of Directors in light of new responsibilities related to his assumption of the...Read more


Evolent Health names Shawn Guertin as new independent nominee for election to its Board of Directors

April 22
Last Trade: 8.98 -0.11 -1.21

Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts. WASHINGTON, April 22, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand...Read more


Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

April 22
Last Trade: 6.84 0.68 11.04

Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in...Read more


Sight Sciences Appoints Gary Burbach to its Board of Directors

April 22
Last Trade: 3.22 -0.07 -2.13

MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company’s Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a...Read more


NurExone Biologic Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario

April 22
Last Trade: 0.67 0.03 4.69

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as...Read more


Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21
Last Trade: 11.01 0.01 0.09

Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. retired from his role as Immunovant CEO and Director Leadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant   IND cleared for a potentially registrational program for IMVT-1402 in...Read more


Apellis Pharmaceuticals Announces Craig Wheeler to Join the Board of Directors

April 21
Last Trade: 17.49 -0.05 -0.29

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. “We are thrilled to welcome Craig to the...Read more


Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

April 21
Last Trade: 12.57 0.05 0.40

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development....Read more


OmniAb Announces Two New Appointments to its Board of Directors

April 21
Last Trade: 1.76 -0.06 -3.30

Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology EMERYVILLE, Calif. / Apr 21, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of...Read more


IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

April 21
Last Trade: 0.30 -0.01 -4.40

Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors. The Advisory Board will provide strategic guidance as IGC advances its Alzheimer's...Read more


OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

April 18
Last Trade: 8.66 0.28 3.34

WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of...Read more


NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

April 17
Last Trade: 17.52 0.05 0.29

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today...Read more


Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

April 17
Last Trade: 20.70 0.09 0.44

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak...Read more


Claritev Further Strengthens Leadership Team as Part of Business Transformation Strategy

April 17
Last Trade: 29.20 0.00 0.00

Jigar S. Patel, MD, Named Chief Medical Officer Fernando Schwartz, Ph.D., Named Chief Artificial Intelligence Officer MCLEAN, Va. / Apr 17, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the following newly created appointments to its senior leadership team to...Read more


Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

April 17
Last Trade: 2.89 0.02 0.70

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the “Board”). Dr. Berman will serve as a non-voting observer to the Board through Atea’s...Read more


Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

April 17
Last Trade: 2.66 0.01 0.38

LEXINGTON, Mass. / Apr 17, 2025 / Business Wire / Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company’s board of directors. “Chip possesses a wealth of experience leading innovative biotechnology companies,” stated Richard H. Douglas,...Read more


CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

April 17
Last Trade: 1.10 -0.06 -5.17

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the...Read more


Adicet Bio Appoints Michael Grissinger to the Board of Directors

April 17
Last Trade: 0.59 -0.03 -4.59

Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions REDWOOD CITY, Calif. & BOSTON / Apr 17, 2025 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its...Read more


Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

April 16
Last Trade: 4.11 -0.01 -0.24

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of...Read more


Conduit Pharmaceuticals Announces Leadership Changes

April 16
Last Trade: 0.56 0.02 3.98

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David...Read more


Alignment Health Strengthens Leadership to Scale its AI-Enabled Medicare Advantage Platform with Two Key Appointments

April 15
Last Trade: 17.52 -0.52 -2.88

ORANGE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced pivotal leadership appointments that underscore its dedication to transforming senior health care through technology and exceptional member care. Dr. Arta Bakshandeh has been named President of AVA®, and Aly Duzich has been promoted to Chief Experience Officer. Driving Next-Generation Innovation For more than 10 years, Alignment...Read more


Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

April 15
Last Trade: 12.20 0.08 0.66

JERSEY CITY, N.J. / Apr 15, 2025 / Business Wire / Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon’s Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board’s Talent Committee. In connection with Ms. Sequeira’s appointment, the size of...Read more


Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

April 15
Last Trade: 11.06 -0.05 -0.45

Vikram Ranade, PhD, appointed as chief business officer  Ranjan Batra, PhD, appointed as chief scientific officer  Oxana Beskrovnaya, PhD, transitioning to chief innovation officer  WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today...Read more


RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

April 15
Last Trade: 0.88 0.0046 0.53

SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of...Read more


Chemomab Therapeutics Announces New Medical and Clinical Appointments

April 15
Last Trade: 1.31 0.02 1.55

David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC, Assumes Chief Development Officer Role TEL AVIV, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage...Read more


NeuPath Health Appoints Stephen Lemieux As President To Drive Next Phase Of Strategic Growth

April 15
Last Trade: 0.20 0.005 2.63

New role strengthens executive team’s ability to leverage operational turnaround, improved cash flow and recently secured credit facility to accelerate growth Mr. Lemieux’s financial expertise, M&A experience and knowledge of NeuPath operations will enable him to contribute effectively from the outset TORONTO / Apr 15, 2025 / Business Wire / NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a...Read more


Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15
Last Trade: 1.20 -0.005 -0.41

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size of the Board to seven Directors. This appointment strengthens Tharimmune's strategic...Read more


Brookdale Senior Living Announces CEO Transition and Board of Directors Refreshment

April 14
Last Trade: 6.30 0.06 0.96

Board Initiates Search for New CEO, Appoints Interim CEO and Establishes Office of the CEO  Mark Fioravanti Appointed as New Independent Director; Frank M. Bumstead Will Not Stand for Reelection at the 2025 Annual Meeting Board to Review Potential Enhancements to Corporate Governance Policies  First Quarter 2025 Preliminary Results Exceed Brookdale Expectations NASHVILLE, Tenn., April 14, 2025 /PRNewswire/ --...Read more


COSCIENS Biopharma Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

April 14
Last Trade: 3.22 0.07 2.22

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, Gilles Gagnon to remain as a Strategic Advisor and Director Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) --...Read more


Myomo Announces Upcoming Changes to its Board of Directors

April 10
Last Trade: 4.84 -0.04 -0.82

BURLINGTON, Mass. / Apr 10, 2025 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since...Read more


Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

April 10
Last Trade: 5.04 -0.33 -6.15

VANCOUVER & DALLAS / Apr 10, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology...Read more


Helix BioPharma Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan

April 10
Last Trade: 0.78 0.00 0.00

April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer (“CEO”) of the Company. A sharpening of Helix’s leadership structure, outgoing CEO, Jacek Antas,...Read more


Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

April 10
Last Trade: 0.48 -0.01 -2.88

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. “With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid...Read more


GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

April 9
Last Trade: 68.42 1.34 2.00

CHICAGO / Apr 09, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, “Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the...Read more


Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

April 9
Last Trade: 33.26 -0.30 -0.89

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development...Read more


Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

April 9
Last Trade: 3.63 -0.03 -0.82

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board...Read more


Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

April 8
Last Trade: 32.20 0.17 0.53

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and...Read more


iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

April 8
Last Trade: 3.28 -0.02 -0.61

NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue...Read more


VentriPoint Diagnostics Appoints Nicolas Coutin to Oversee Clinical Affairs

April 8
Last Trade: 0.15 0.00 0.00

Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company’s ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO. Dr. Coutin was part of the...Read more


Aspira Women's Health Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement

April 8
Last Trade: 0.08 0.00 0.00

New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These...Read more


Krystal Biotech: Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

April 7
Last Trade: 168.06 -1.06 -0.63

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over...Read more


Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors

April 7
Last Trade: 10.43 -0.75 -6.71

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. “On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared...Read more


Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

April 7
Last Trade: 13.50 -0.06 -0.44

Mr. Ajer was most recently Chief Commercial Officer at BioMarin  WALTHAM, Mass. / Apr 07, 2025 / Business Wire / Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization...Read more


Treace Medical Concepts Announces Upcoming Board Chair Transition

April 7
Last Trade: 6.72 0.06 0.90

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace,...Read more


MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

April 7
Last Trade: 9.17 -0.10 -1.08

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical...Read more


Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

April 7
Last Trade: 1.64 -3.72 -69.40

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the...Read more


Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

April 4
Last Trade: 106.73 0.97 0.92

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas  SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished...Read more


Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

April 4
Last Trade: 0.09 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee. Mr. Farlinger is...Read more


Telix Pharmaceuticals: Anne Whitaker Appointed as Non-Executive Director

April 3
Last Trade: 18.80 -0.42 -2.19

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years’ global corporate experience spanning large pharmaceutical, biotech and...Read more


Ardent Health Appoints Robert DeMichiei to Board of Directors

April 3
Last Trade: 12.52 -0.04 -0.32

BRENTWOOD, Tenn. / Apr 03, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial...Read more


Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

April 3
Last Trade: 29.61 0.18 0.61

PLYMOUTH MEETING, Pa. / Apr 03, 2025 / Business Wire / Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of...Read more


PanGenomic Health Announces Management Change

April 3
Last Trade: 0.24 0.00 0.00

Vancouver, British Columbia, Canada – TheNewswire - April 3, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the resignation of Tammy Gillis as CFO of the Company. Ms. Gillis will continue to act as a financial consultant to the Company, and in particular, assist with completion of the year end audit process for the last fiscal year. Current director Francisco Kent Carasquero will assume the role...Read more


Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

April 2
Last Trade: 5.38 -0.14 -2.54

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,”...Read more


Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

April 2
Last Trade: 0.49 0.02 4.82

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and...Read more


HCA Healthcare Names Monica Cintado as Senior Vice President of Development

April 1
Last Trade: 327.92 -13.49 -3.95

Joseph A. Sowell to retire after more than 15 years of service NASHVILLE, Tenn. / Apr 01, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Monica Cintado has been appointed as senior vice president of development, effective immediately. In this role, Cintado will lead HCA Healthcare’s enterprise development strategy, overseeing mergers, acquisitions,...Read more


Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

April 1
Last Trade: 10.27 0.18 1.78

FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in...Read more


Phathom Pharmaceuticals Announces Leadership Succession

April 1
Last Trade: 4.11 -0.01 -0.24

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as...Read more


Codexis Appoints Cynthia Collins to Board of Directors

April 1
Last Trade: 2.26 -0.04 -1.74

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board of Directors. “I am thrilled to welcome Cindy to our Board,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “She has been at the forefront of...Read more


Esperion Appoints Robert E. Hoffman to Board of Directors

April 1
Last Trade: 0.92 0.04 4.39

Veteran Industry Executive Brings Decades of Financial and Leadership Experience  ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr.,...Read more


Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

April 1
Last Trade: 12.26 0.28 2.34

SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish...Read more


Korro Bio Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

April 1
Last Trade: 18.09 0.65 3.73

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer. “We are excited to welcome Dr. Vincent, whose extensive drug development experience...Read more


Journey Medical Appoints Ramsey Alloush as Chief Operating Officer

April 1
Last Trade: 7.47 -0.09 -1.19

SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General...Read more


InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

April 1
Last Trade: 4.97 -0.03 -0.60

The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% ROCHESTER HILLS, Mich. / Apr 01, 2025 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that...Read more


Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

April 1
Last Trade: 1.20 -0.06 -4.76

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today...Read more


Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

April 1
Last Trade: 3.01 0.00 0.00

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio,” said Aoife...Read more


Ardent Health Announces Appointment of Chief Operating Officer and Senior Leadership Promotions

March 31
Last Trade: 12.52 -0.04 -0.32

BRENTWOOD, Tenn. / Mar 31, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Dave Caspers as chief operating officer. In this new role, Caspers will oversee operations across Ardent Health, which includes 30 hospitals and 280 sites of care in six states. He will be responsible for executing on strategic growth...Read more


Repare Therapeutics Announces Leadership Transitions

March 31
Last Trade: 1.25 -0.08 -6.02

Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue other opportunities CAMBRIDGE, Mass. & MONTREAL / Mar 31, 2025 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today...Read more


PepGen Announces Appointment of Two New Directors to its Board

March 31
Last Trade: 1.53 -0.15 -8.93

BOSTON / Mar 31, 2025 / Business Wire / PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive...Read more


BetterLife Pharma Appoints New Director

March 31
Last Trade: 0.10 0.00 0.00

VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public...Read more


Alector Provides Executive Leadership Update

March 28
Last Trade: 1.14 -0.04 -3.39

Giacomo Salvadore, M.D., appointed Chief Medical Officer Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to...Read more


Traws Pharma Announces Management Updates

March 28
Last Trade: 1.55 0.02 1.31

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced...Read more


Becton Dickinson Names Gregory J. Hayes to Board of Directors

March 27
Last Trade: 205.08 0.63 0.31

FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of...Read more


Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

March 27
Last Trade: 8.42 -0.18 -2.09

Felix J. Baker, Ph.D., to become chairman of Board of Directors Alessandro Riva, M.D., joins Board of Directors and Fabrice André, M.D., Ph.D., joins Clinical Advisory Board Eric Westin, M.D., promoted to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development CAMBRIDGE, England & BOSTON / Mar 27, 2025 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical...Read more


TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

March 27
Last Trade: 1.60 -0.12 -6.98

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement,...Read more


Beta Bionics Announces Board Appointment of Gerard Michel

March 27
Last Trade: 0 0.00 0.00

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company. “We are excited to...Read more


Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

March 26
Last Trade: 3.85 -0.11 -2.78

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years...Read more


Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

March 26
Last Trade: 0.65 -0.02 -2.75

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan’s investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder...Read more


Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

March 26
Last Trade: 4.78 -0.10 -2.05

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE